FCER2

Summary

FCER2 (Fc epsilon receptor II, HGNC:3612) is a protein-coding gene on chromosome 19p13.2, encoding Low affinity immunoglobulin epsilon Fc receptor (P06734). Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21.

The protein encoded by this gene is a B-cell specific antigen, and a low-affinity receptor for IgE. It has essential roles in B cell growth and differentiation, and the regulation of IgE production. This protein also exists as a soluble secreted form, then functioning as a potent mitogenic growth factor. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 2208 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 64 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001220500

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3612
Approved symbol	FCER2
Name	Fc epsilon receptor II
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	CLEC4J, CD23, FCErII, FcepsilonRII
Ensembl gene	ENSG00000104921
Ensembl biotype	protein_coding
OMIM	151445
Entrez	2208

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 4 protein_coding, 3 retained_intron

ENST00000346664, ENST00000360067, ENST00000593418, ENST00000597312, ENST00000597921, ENST00000597934, ENST00000598803

RefSeq mRNA: 3 — MANE Select: NM_001220500 NM_001207019, NM_001220500, NM_002002

CCDS: CCDS12184

Canonical transcript exons

ENST00000597921 — 11 exons

Exon	Start	End
ENSE00002978935	7702015	7702131
ENSE00003182652	7688776	7689430
ENSE00003487649	7696825	7696914
ENSE00003515231	7697013	7697075
ENSE00003529945	7699739	7699845
ENSE00003537804	7698741	7698854
ENSE00003584257	7698356	7698409
ENSE00003609356	7697236	7697298
ENSE00003622475	7697527	7697589
ENSE00003628227	7690159	7690265
ENSE00003672754	7690406	7690557

Expression profiles

Bgee: expression breadth ubiquitous, 147 present calls, max score 95.26.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 6.6674 / max 945.2110, expressed in 140 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178882	4.0229	74
178870	1.0905	81
178879	1.0310	46
178869	0.1198	31
178871	0.0913	15
178876	0.0772	16
178874	0.0768	12
178880	0.0548	19
178873	0.0287	11
178878	0.0224	8

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	95.26	gold quality
granulocyte	CL:0000094	92.62	gold quality
spleen	UBERON:0002106	90.11	gold quality
lymph node	UBERON:0000029	87.91	gold quality
vermiform appendix	UBERON:0001154	81.06	gold quality
frontal pole	UBERON:0002795	79.65	gold quality
blood	UBERON:0000178	79.03	gold quality
paraflocculus	UBERON:0005351	78.41	gold quality
middle frontal gyrus	UBERON:0002702	77.41	gold quality
caecum	UBERON:0001153	77.21	gold quality
leukocyte	CL:0000738	76.34	gold quality
hair follicle	UBERON:0002073	76.15	gold quality
buccal mucosa cell	CL:0002336	76.07	gold quality
monocyte	CL:0000576	75.04	gold quality
mononuclear cell	CL:0000842	74.94	gold quality
mucosa of transverse colon	UBERON:0004991	72.76	gold quality
endometrium epithelium	UBERON:0004811	70.46	gold quality
small intestine Peyer’s patch	UBERON:0003454	70.34	gold quality
Brodmann (1909) area 10	UBERON:0013541	70.34	gold quality
bone marrow cell	CL:0002092	69.56	gold quality
tonsil	UBERON:0002372	69.21	gold quality
tongue squamous epithelium	UBERON:0006919	68.94	gold quality
superficial temporal artery	UBERON:0001614	68.32	silver quality
small intestine	UBERON:0002108	68.18	gold quality
diaphragm	UBERON:0001103	67.88	gold quality
bone marrow	UBERON:0002371	67.48	gold quality
epithelial cell of pancreas	CL:0000083	66.70	gold quality
epithelium of nasopharynx	UBERON:0001951	66.67	gold quality
cerebellar vermis	UBERON:0004720	65.83	gold quality
rectum	UBERON:0001052	65.73	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	132.74
E-CURD-122	yes	103.78
E-HCAD-1	yes	98.11
E-CURD-88	yes	53.32
E-ANND-3	yes	13.57
E-CURD-77	no	606.48

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): BCL6, EGR1, IRF4, NFATC3, NFKB2, NOTCH2, PAX5, PRDM1, RBPJ, REL, SPI1, SPIB, SPIC, STAT6, TCF3

miRNA regulators (miRDB)

39 targeting FCER2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-3147	99.52	66.34	388
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-452-3P	99.01	66.25	1241
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-5572	98.55	65.84	970
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-3179	98.22	65.90	1445
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-4691-3P	98.11	66.83	1204
HSA-MIR-6819-5P	97.96	66.59	1071
HSA-MIR-6737-5P	97.75	66.54	1044
HSA-MIR-6812-5P	97.56	65.39	1059
HSA-MIR-3189-5P	97.55	66.71	655
HSA-MIR-6855-5P	97.51	66.03	830
HSA-MIR-3157-5P	97.41	67.61	998
HSA-MIR-342-5P	97.25	64.10	817
HSA-MIR-1913	97.07	66.20	1417

Literature-anchored findings (GeneRIF, showing 40)

• cd23 negativity is rare in typical b-cell CLL; negativity in patients with CD19+/CD5+ is suggestive of mantle cell leukemia (PMID:11920534)
• prognostic significance of soluble CD23 in advanced stages of B-chronic lymphocytic leukemia and its role as an indicator for aggressive or indolent courses of disease. (PMID:12002758)
• a review on the domains and functions of the cd23 receptor (PMID:12022472)
• upstream regions of the CD23a and CD23b isoform coding sequences show distinct sensitivities to agents which induce CD23 protein expression at the plasma membrane (PMID:12070780)
• Investigation of several stimulators to promote CD23a expression on CLL vs. normal B-cells confirmed a different CD23 regulation in B-CLL. CD23a is always predominantly expressed (constant ratio of CD23a:CD23b). (PMID:12127553)
• CD23 expression in chronic lymphocytic leukemia was 53.9 times higher than in mantle-cell llymphoma. (PMID:12127555)
• At term, the percentage of CD21(+) and CD23(+) B cells was comparable to the adult (PMID:12149502)
• promoter is a target for NF-AT transcription factors in B-CLL cells (PMID:12379312)
• The data show that monocyte-derived DC express the P2X7 receptor whose activation opens a cation-selective channel, and which leads to rapid and near complete shedding of CD23. (PMID:12456589)
• Expression of this antigen may identify prognostically favorable subgroups of diffuse large B-cell lymphoma. (PMID:12576441)
• Pax-5 is a key regulator of the B-cell-restricted expression of the CD23a isoform. (PMID:12731041)
• ADAM8, ADAM15, and MDC-L, but not ADAM17, catalyzed ectodomain shedding of CD23, the low affinity IgE receptor. (PMID:12777399)
• role of the CD23/nitric oxide pathway in the control of the cytoadherence of Plasmodium falciparum parasitized red blood cells on endothelial cells (PMID:15272865)
• Data show that gamma-irradiation not only induced CD23 expression, but also augmented the interleukin-4-induced surface CD23 levels. (PMID:15469741)
• Downregulation of CD23 antigens activity are early steps in PI-induced apoptosis of B-cell chronic lymphocytic leukemia lymphocytes and may be part of the full apoptotic response. (PMID:15565166)
• Results suggest that CD23 should be included in the panel of antibodies currently used to characterize mediastinal large B-cell lymphomas. (PMID:15569053)
• review of mechanisms leading to the upregulation of CD23 in the leukemic cells and review of the potential functions of CD23 as well as its regulation by Notch2 in B-CLL (PMID:15621797)
• CD21 and CD23a are common targets for B lymphotropic gammaherpesviruses. (PMID:15795251)
• In humans, in contrast to what was previously found in mice, intestinal cells coexpress CD23a and CD23b, and the two splice forms show different localizations in polarized cells. (PMID:15843555)
• Retinoic acid inhibits CD40 plus IL-4 mediated IgE production through alterations of sCD23, sCD54 and IL-6 production (PMID:15883744)
• marked inhibition of cell cluster formation and proliferation is achieved by antibody treatment against the CD23 mature B cell surface marker expressed in LCL41 cells (PMID:16009564)
• Results describe the production of a recombinant form of human soluble CD23 with similar proinflammatory properties as the native protein. (PMID:16083870)
• CD23 encodes a functional IgE receptor on human intestinal epithelial cells and this epithelial receptor is likely to play an important role in food allergies. (PMID:16143132)
• CD23 is involved in both up- and down-regulation of IgE; CD23 can bind both its ligands, IgE and CD21, simultaneously. (PMID:16172256)
• The high-resolution crystal structures of the human CD23 lectin domain in the presence and absence of Ca2+ was solved. (PMID:16765898)
• CD23a is expressed normally on human IECs, and in the presence of IgE can function as an antigen-sampling mechanism capable of activating subepithelial mast cells. (PMID:16831589)
• low levels of c-Rel are the underlying cause of aberrant CD23 expression in non-X-linked hyper-IgM syndrome B cells (PMID:16896156)
• Our results indicate that CD23 expression in these human intestinal epithelial cells is mediated through the p38 MAPK pathway. (PMID:16899715)
• R62W influences the stability of membrane CD23 molecules due to possibly diminished N-glycosylation. (PMID:17301828)
• There is an unexpectedly high frequency of CD23 expression in follicular lymphomas in general, which is even more pronounced in inguinal nodes. (PMID:17493235)
• The interaction between alphavbeta5 and sCD23 indicates that integrins deliver to cells important signals initiated by soluble ligands without the requirement for interactions with RGD motifs in their common ligands. (PMID:17540777)
• the CD23 monomers inhibit and the oligomer stimulates IgE synthesis in human B cells after heavy chain switching to IgE (PMID:17576766)
• Transgenic CD23 enhances antibody and T-cell responses to IgE-complexed antigen, while it negatively regulates the total antibody response to a variety of antigens. (PMID:17635803)
• lumiliximab may be an effective treatment alone or in combination with rituximab or chemotherapy agents in chronic lymphocytic leukemia or other CD23-overexpressing B-cell malignancies (PMID:18032710)
• correlation of CD23 expression in B-chronic lymphocytic leukaemia & clinical parameters; CD23 expression is significantly decreased in patients with extremely high lymphocyte counts (PBL counts of >100 x 10(9)/l) & in the advanced stages of disease (PMID:18183502)
• The distinct punctate CD23 staining for Merkel cell carcinoma may be helpful in differentiating it from small cell carcinoma. (PMID:18616759)
• higher expression levels in adenoid tissue of children with house dust mite allergies (PMID:18657051)
• CD23 is a useful marker in distinguishing mediastinal diffuse large B-cell lymphoma and classical Hodgkin lymphoma in mediastinal biopsies. (PMID:19223373)
• The absolute number of B lymphocytes and the percentage of naive cells (CD23-/CD27-) decreased with age whereas there was an increase in memory cells (CD27+). (PMID:19290077)
• MyD88-dependent Toll-like receptor (TLR)4 agonists may enhance allergic responses by inducing the production of both CD23 and MMP9, resulting in increased cleavage of membrane CD23 and soluble CD23 accumulation. (PMID:19635918)

Cross-species orthologs

22 orthologs

Organism	Symbol	Gene ID
danio_rerio	asgr1c.2	ENSDARG00000046092
danio_rerio	asgrl1	ENSDARG00000046142
danio_rerio	si:dkey-61f9.1	ENSDARG00000070414
danio_rerio	asgr1a	ENSDARG00000095963
danio_rerio	si:cabz01007816.2	ENSDARG00000102537
danio_rerio	asgr1b	ENSDARG00000103480
danio_rerio	si:ch211-283g2.5	ENSDARG00000108953
danio_rerio		ENSDARG00000111755
danio_rerio		ENSDARG00000112842
mus_musculus	Fcer2a	ENSMUSG00000005540
rattus_norvegicus	Fcer2	ENSRNOG00000001005
drosophila_melanogaster	tfc	FBGN0035199
drosophila_melanogaster	CG14866	FBGN0038315
drosophila_melanogaster	lectin-46Cb	FBGN0040092
drosophila_melanogaster	lectin-46Ca	FBGN0040093
drosophila_melanogaster	lectin-33A	FBGN0040096
drosophila_melanogaster	CG34033	FBGN0054033
caenorhabditis_elegans	clec-87	WBGENE00007709
caenorhabditis_elegans	clec-91	WBGENE00014117
caenorhabditis_elegans		WBGENE00016088
caenorhabditis_elegans		WBGENE00018692
caenorhabditis_elegans		WBGENE00019606

Paralogs (14): CD209 (ENSG00000090659), CLEC4M (ENSG00000104938), CLEC4A (ENSG00000111729), CD207 (ENSG00000116031), CLEC10A (ENSG00000132514), ASGR1 (ENSG00000141505), CLEC4F (ENSG00000152672), ASGR2 (ENSG00000161944), CLEC4E (ENSG00000166523), CLEC4D (ENSG00000166527), CLEC4G (ENSG00000182566), CLEC17A (ENSG00000187912), CLEC4C (ENSG00000198178), CLEC6A (ENSG00000205846)

Protein

Protein identifiers

Low affinity immunoglobulin epsilon Fc receptor — P06734 (reviewed: P06734)

Alternative names: BLAST-2, C-type lectin domain family 4 member J, Fc-epsilon-RII, Immunoglobulin E-binding factor, Lymphocyte IgE receptor

All UniProt accessions (3): P06734, K3W4U1, M0R1R5

UniProt curated annotations — full annotation on UniProt →

Function. Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B cells. On B cells, initiates IgE-dependent antigen uptake and presentation to T cells. On macrophages, upon IgE binding and antigen cross-linking induces intracellular killing of parasites through activation of L-Arginine-nitric oxide pathway.

Subunit / interactions. Homotrimer. Interacts (via C-type lectin domain) with IGHE (via CH3 region); this interaction regulates IgE homeostasis. Interacts (via the C-terminus) with CR2/CD21 (via Sushi domain 1 and 2).

Subcellular location. Cell membrane. Secreted.

Tissue specificity. Detected in urine (at protein level).

Post-translational modifications. N- and O-glycosylated. The secreted form sCD23 is produced by ADAM10-mediated ectodomain shedding.

Miscellaneous. There are two kinds of Fc receptors for IgE, which differ in both structure and function: high affinity receptors on basophils and mast cells and low affinity receptors on lymphocytes and monocytes.

RefSeq proteins (3): NP_001193948, NP_001207429, NP_001993 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001304	C-type_lectin-like	Domain
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR033989	CD209-like_CTLD	Domain
IPR050111	C-type_lectin/snaclec_domain	Family

Pfam: PF00059

UniProt features (47 total): strand 14, binding site 4, disulfide bond 4, sequence variant 3, turn 3, repeat 3, chain 2, region of interest 2, lipid moiety-binding region 2, glycosylation site 2, topological domain 2, helix 2, site 1, sequence conflict 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

23 structures.

PDB	Method	Resolution (Å)
2H2T	X-RAY DIFFRACTION	1.3
2H2R	X-RAY DIFFRACTION	1.5
6Y0M	X-RAY DIFFRACTION	1.5
6Y0L	X-RAY DIFFRACTION	1.65
4J6J	X-RAY DIFFRACTION	1.9
4J6P	X-RAY DIFFRACTION	1.9
4GJ0	X-RAY DIFFRACTION	1.95
4G9A	X-RAY DIFFRACTION	2
4GK1	X-RAY DIFFRACTION	2.24
4G96	X-RAY DIFFRACTION	2.25
4GI0	X-RAY DIFFRACTION	2.27
4J6K	X-RAY DIFFRACTION	2.3
4J6M	X-RAY DIFFRACTION	2.48
4J6Q	X-RAY DIFFRACTION	2.54
4GJX	X-RAY DIFFRACTION	2.8
4J6N	X-RAY DIFFRACTION	2.85
4EZM	X-RAY DIFFRACTION	3.1
4J6L	X-RAY DIFFRACTION	3.15
4KI1	X-RAY DIFFRACTION	3.2
4GKO	X-RAY DIFFRACTION	3.3
5LGK	X-RAY DIFFRACTION	3.5
1T8C	SOLUTION NMR
1T8D	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P06734-F1	86.76	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 149–150 (cleavage)

Ligand- & substrate-binding residues (4): 249; 251; 269; 270

Post-translational modifications (2): 17, 18

Disulfide bonds (4): 160–288, 163–174, 191–282, 259–273

Glycosylation sites (2): 63, 296

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-2197563	NOTCH2 intracellular domain regulates transcription
R-HSA-6783783	Interleukin-10 signaling
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling

MSigDB gene sets: 262 (showing top): REACTOME_SIGNALING_BY_NOTCH, LU_IL4_SIGNALING, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, MODULE_64, GOCC_CELL_SURFACE, MODULE_478, CROONQUIST_NRAS_SIGNALING_UP, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_B_CELL_MEDIATED_IMMUNITY, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, GOBP_FC_EPSILON_RECEPTOR_SIGNALING_PATHWAY, GOBP_MYELOID_LEUKOCYTE_ACTIVATION, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION

GO Biological Process (9): B cell antigen processing and presentation (GO:0002450), positive regulation of humoral immune response mediated by circulating immunoglobulin (GO:0002925), immune response (GO:0006955), positive regulation of gene expression (GO:0010628), Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096), macrophage activation (GO:0042116), defense response to bacterium (GO:0042742), Fc receptor-mediated immune complex endocytosis (GO:0160006), Fc-epsilon receptor signaling pathway (GO:0038095)

GO Molecular Function (8): protease binding (GO:0002020), integrin binding (GO:0005178), low-affinity IgE receptor activity (GO:0019769), IgE binding (GO:0019863), carbohydrate binding (GO:0030246), pattern recognition receptor activity (GO:0038187), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (5): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), extracellular exosome (GO:0070062), extracellular region (GO:0005576), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Signaling by Interleukins	2
Signaling by NOTCH2	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cellular anatomical structure	2
B cell mediated immunity	1
antigen processing and presentation	1
humoral immune response mediated by circulating immunoglobulin	1
positive regulation of immunoglobulin mediated immune response	1
positive regulation of humoral immune response	1
regulation of humoral immune response mediated by circulating immunoglobulin	1
immune system process	1
response to stimulus	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
Fc receptor mediated stimulatory signaling pathway	1
phagocytosis	1
Fc-gamma receptor signaling pathway	1
myeloid leukocyte activation	1
defense response	1
response to bacterium	1
receptor-mediated endocytosis	1
Fc receptor signaling pathway	1
enzyme binding	1
signaling receptor binding	1
protein-containing complex binding	1
cell adhesion molecule binding	1
IgE receptor activity	1
immunoglobulin binding	1
signaling receptor activity	1
cation binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
extracellular vesicle	1

Protein interactions and networks

STRING

1092 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FCER2	CR2	P20023	936
FCER2	FCGR1A	P12314	674
FCER2	RBMS1	P29558	640
FCER2	FCGR3A	P08637	615
FCER2	PAX5	Q02548	615
FCER2	FCGR3B	O75015	601
FCER2	IL4	P05112	593
FCER2	ADAM10	O14672	551
FCER2	CXCL16	Q9H2A7	549
FCER2	PDCL	Q13371	542
FCER2	GLCCI1	Q86VQ1	540
FCER2	FCAR	P24071	511
FCER2	CD5	P06127	507
FCER2	EFNA2	O43921	497
FCER2	NOTCH2	Q04721	490

IntAct

10 interactions, top by confidence:

A	B	Type	Score
FCER2	CDH2	psi-mi:“MI:0407”(direct interaction)	0.600
CDH2	FCER2	psi-mi:“MI:0403”(colocalization)	0.600
FCER2	ATF7	psi-mi:“MI:0915”(physical association)	0.560
FGFR2	FCER2	psi-mi:“MI:0407”(direct interaction)	0.560
FCER2	FGFR2	psi-mi:“MI:0407”(direct interaction)	0.560
CR2	FCER2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (9): ATF7 (Two-hybrid), FCER2 (Reconstituted Complex), XRCC6 (Reconstituted Complex), FCER2 (Affinity Capture-Western), RNF144B (Affinity Capture-Western), NOTCH2 (Affinity Capture-Western), FCER2 (Affinity Capture-Western), FCER2 (Affinity Capture-RNA), FCER2 (Affinity Capture-RNA)

ESM2 similar proteins: A3FM55, A7X401, A7X406, A7X409, A7X413, B0VXV0, B0VXV1, B4XSY7, B4XSY8, B4XSZ1, B4XT08, C0HKZ6, D3ZWT9, I7JUQ0, J3RY43, J3S3U6, J3SBN9, P02707, P06734, P0DJL4, P14371, P17346, P20693, P25031, P81017, P81116, Q38L02, Q4PRD2, Q64335, Q67EQ0, Q67EQ1, Q696W1, Q69FH1, Q6EIG7, Q6T7B5, Q71RQ9, Q7LZK5, Q7T2Q0, Q7T2Q1, Q8CJ91

Diamond homologs: A0ZT93, B0VXV2, B4XT08, B5U6Y6, B5U6Y7, C0HKZ7, O60449, P05140, P06027, P06734, P0DJL5, P10716, P13611, P14371, P20693, P34472, P55066, P55067, P81018, P81282, P81996, Q01758, Q02988, Q26627, Q28062, Q28670, Q28858, Q4PRD0, Q4TU93, Q4V885, Q61830, Q62059, Q64449, Q66S03, Q6X5S2, Q6X5S3, Q6X5S5, Q6X5S6, Q6X5S7, Q6X5S8

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
PRDM1	“down-regulates quantity by repression”	FCER2	“transcriptional regulation”
BCL6	“down-regulates quantity by repression”	FCER2	“transcriptional regulation”
IRF4	“up-regulates quantity by expression”	FCER2	“transcriptional regulation”
EGR1	“down-regulates quantity by repression”	FCER2	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1391 predictions. Top by Δscore:

Variant	Effect	Δscore
19:7689426:AGTTG:A	acceptor_gain	1.0000
19:7689427:GTTG:G	acceptor_gain	1.0000
19:7689428:TTG:T	acceptor_gain	1.0000
19:7689429:TG:T	acceptor_gain	1.0000
19:7689431:C:CC	acceptor_gain	1.0000
19:7690153:CCTCA:C	donor_loss	1.0000
19:7690154:CTCAC:C	donor_loss	1.0000
19:7690155:TCAC:T	donor_loss	1.0000
19:7690156:CA:C	donor_loss	1.0000
19:7690264:TC:T	acceptor_gain	1.0000
19:7690265:CC:C	acceptor_gain	1.0000
19:7690265:CCTGG:C	acceptor_loss	1.0000
19:7690266:C:CC	acceptor_gain	1.0000
19:7690512:C:CT	acceptor_gain	1.0000
19:7696816:CACA:C	donor_gain	1.0000
19:7696824:CCG:C	donor_gain	1.0000
19:7696916:T:C	acceptor_gain	1.0000
19:7697234:AC:A	donor_gain	1.0000
19:7697235:CC:C	donor_gain	1.0000
19:7697299:C:CC	acceptor_gain	1.0000
19:7697303:T:TC	acceptor_gain	1.0000
19:7702013:A:AC	donor_gain	1.0000
19:7702014:C:CC	donor_gain	1.0000
19:7702014:CT:C	donor_gain	1.0000
19:7702014:CTCA:C	donor_gain	1.0000
19:7702017:A:AC	donor_gain	1.0000
19:7702018:C:CC	donor_gain	1.0000
19:7689424:CCAGT:C	acceptor_gain	0.9900
19:7689425:CAGT:C	acceptor_gain	0.9900
19:7689428:T:C	acceptor_gain	0.9900

AlphaMissense

2109 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:7689355:C:A	W268C	0.999
19:7689355:C:G	W268C	0.999
19:7689424:C:A	W245C	0.999
19:7689424:C:G	W245C	0.999
19:7690227:C:A	W220C	0.998
19:7690227:C:G	W220C	0.998
19:7690475:C:A	W184C	0.998
19:7690475:C:G	W184C	0.998
19:7690185:C:A	W234C	0.997
19:7690185:C:G	W234C	0.997
19:7690526:C:A	W167C	0.997
19:7690526:C:G	W167C	0.997
19:7689357:A:G	W268R	0.996
19:7689357:A:T	W268R	0.996
19:7690455:C:T	C191Y	0.995
19:7689319:C:A	W280C	0.994
19:7689319:C:G	W280C	0.994
19:7690455:C:G	C191S	0.992
19:7690456:A:T	C191S	0.992
19:7690506:C:G	C174S	0.992
19:7690507:A:T	C174S	0.992
19:7689356:C:G	W268S	0.991
19:7690229:A:G	W220R	0.991
19:7690229:A:T	W220R	0.991
19:7690260:G:C	F209L	0.991
19:7690260:G:T	F209L	0.991
19:7690261:A:C	F209C	0.991
19:7690262:A:G	F209L	0.991
19:7690454:A:C	C191W	0.991
19:7689314:C:G	C282S	0.990

dbSNP variants (sampled 300 via entrez): RS1000025918 (19:7700671 T>A,C), RS1000285709 (19:7703464 T>C), RS1000451044 (19:7703889 C>A), RS1000481356 (19:7698611 A>G,T), RS1000558528 (19:7696659 C>G), RS1000608019 (19:7700260 A>AGTTTTCCCCTCT), RS1000623508 (19:7701897 C>T), RS1000675696 (19:7694012 G>A), RS1000746650 (19:7692126 G>A,T), RS1001046174 (19:7693719 G>A,T), RS1001079797 (19:7701713 T>C), RS1001196356 (19:7688526 T>C,G), RS1001558559 (19:7697871 A>C), RS1001783718 (19:7693102 A>G), RS1002181926 (19:7699885 AT>A)

Disease associations

OMIM: gene MIM:151445 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003262_344	Post bronchodilator FEV1	2.000000e-06
GCST006585_918	Blood protein levels	2.000000e-25

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004314	forced expiratory volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2940 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 21,247 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL279786	BATIMASTAT	2	21,247

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs28364072	FCER2		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Fc epsilon receptors

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
IgE heavy chain	Binding	7.0	pKd

ChEMBL bioactivities

63 potent at pChembl≥5 of 65 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.92	IC50	12	nM	CHEMBL115348
7.89	IC50	13	nM	CHEMBL118054
7.80	IC50	16	nM	CHEMBL324564
7.70	IC50	20	nM	CHEMBL115326
7.70	IC50	20	nM	CHEMBL323228
7.70	IC50	20	nM	CHEMBL432583
7.70	IC50	20	nM	CHEMBL322050
7.52	IC50	30	nM	CHEMBL424251
7.52	IC50	30	nM	CHEMBL115211
7.40	IC50	40	nM	CHEMBL114657
7.40	IC50	40	nM	CHEMBL114427
7.30	IC50	50	nM	CHEMBL320799
7.22	IC50	60	nM	CHEMBL326148
7.16	IC50	70	nM	CHEMBL2112477
7.16	IC50	70	nM	CHEMBL2111687
7.10	IC50	80	nM	CHEMBL116506
7.10	IC50	80	nM	CHEMBL110713
7.00	IC50	100	nM	CHEMBL116435
7.00	IC50	100	nM	CHEMBL324205
7.00	IC50	100	nM	CHEMBL316550
7.00	IC50	100	nM	BATIMASTAT
7.00	IC50	100	nM	CHEMBL115046
7.00	IC50	100	nM	CHEMBL326555
7.00	IC50	100	nM	CHEMBL320798
7.00	IC50	100	nM	CHEMBL110546
7.00	EC50	100	nM	CHEMBL318079
6.96	EC50	110	nM	CHEMBL104519
6.89	IC50	130	nM	CHEMBL326814
6.89	IC50	130	nM	CHEMBL324723
6.89	IC50	130	nM	CHEMBL114332
6.80	IC50	160	nM	CHEMBL113764
6.70	IC50	200	nM	CHEMBL420077
6.68	IC50	210	nM	CHEMBL325608
6.66	IC50	220	nM	CHEMBL108412
6.64	IC50	230	nM	CHEMBL108737
6.50	EC50	313	nM	CHEMBL104279
6.50	IC50	320	nM	CHEMBL110667
6.42	IC50	380	nM	CHEMBL433197
6.40	IC50	400	nM	CHEMBL322138
6.22	IC50	600	nM	CHEMBL108842
6.12	IC50	760	nM	CHEMBL106444
6.00	IC50	1000	nM	CHEMBL440712
6.00	IC50	1000	nM	CHEMBL106233
6.00	IC50	1000	nM	CHEMBL11306
6.00	IC50	1000	nM	CHEMBL92762
5.85	EC50	1400	nM	CHEMBL104333
5.80	IC50	1600	nM	CHEMBL94368
5.72	IC50	1900	nM	CHEMBL96654
5.71	EC50	1940	nM	CHEMBL104691
5.52	IC50	3000	nM	CHEMBL326985

PubChem BioAssay actives

63 with measured affinity, of 92 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R)-N-hydroxy-2-[[(2E)-2-hydroxyimino-2-phenylethyl]sulfanylmethyl]-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.0120	uM
methyl 2-[(2S,3R)-3-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]carbamoyl]-2-(hydroxycarbamoyl)-5-methylhexyl]sulfanylacetate	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.0130	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(phenacylsulfanylmethyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.0160	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-(1-benzothiophen-2-ylmethyl)-N’,3-dihydroxybutanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.0200	uM
(2R,3S)-N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-N’,3-dihydroxy-2-(naphthalen-2-ylmethyl)butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.0200	uM
(2R,3S)-N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-N’,3-dihydroxy-2-(quinolin-3-ylmethyl)butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.0200	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-(phenacylsulfanylmethyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.0200	uM
(2S,3R)-2-(benzylsulfanylmethyl)-N-hydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)butanediamide	44538: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 30-100	ic50	0.0300	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-(thiophen-2-ylsulfanylmethyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.0300	uM
(2S,3R)-N-hydroxy-2-[(4-hydroxyphenyl)sulfanylmethyl]-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)butanediamide	44539: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 40-80	ic50	0.0400	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(phenylsulfanylmethyl)butanediamide	44539: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 40-80	ic50	0.0400	uM
methyl 4-[(2S,3R)-2-(hydroxycarbamoyl)-5-methyl-3-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]hexyl]sulfanylbenzoate	44670: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 50-150	ic50	0.0500	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-[[(2E)-2-(4-chlorophenyl)-2-hydroxyiminoethyl]sulfanylmethyl]-N’-hydroxy-2-(2-methylpropyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.0600	uM
(3S)-N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-N’,3-dihydroxy-2-[[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]methyl]butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.0700	uM
(3S)-N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-N’,3-dihydroxy-2-[[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]methyl]butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.0700	uM
(2R,3S)-N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-2-[(7-fluoronaphthalen-2-yl)methyl]-N’,3-dihydroxybutanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.0800	uM
(2S,3R)-N-hydroxy-2-[[(2E)-2-methoxyimino-2-phenylethyl]sulfanylmethyl]-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.0800	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-[(7-fluoronaphthalen-2-yl)methyl]-N’,3-dihydroxybutanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.1000	uM
(2S,3R)-3-(1-benzofuran-2-ylmethyl)-N,2-dihydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.1000	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-[(4-nitrophenyl)sulfanylmethyl]butanediamide	44534: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 100-300	ic50	0.1000	uM
methyl 2-[(2S,3R)-2-(hydroxycarbamoyl)-5-methyl-3-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]hexyl]sulfanylbenzoate	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.1000	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-3-[[(2E)-2-hydroxyimino-2-phenylethyl]sulfanylmethyl]-2-(2-methylpropyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.1000	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-benzyl-N’-hydroxy-3-[[(2Z)-2-methoxyimino-2-phenylethyl]sulfanylmethyl]butanediamide	44534: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 100-300	ic50	0.1000	uM
(2R,3S)-3-[(2-amino-2-oxoethyl)sulfanylmethyl]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-2-(2-methylpropyl)butanediamide	44533: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 100-200	ic50	0.1000	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide	44531: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line)	ic50	0.1000	uM
(3Z)-3-[(5-methoxy-1-methylindol-3-yl)methylidene]-N-methyl-2-oxo-1H-indole-5-carboxamide	166535: Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT release	ec50	0.1000	uM
(3Z)-3-[(5-methoxy-1-methylindol-3-yl)methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide	166535: Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT release	ec50	0.1100	uM
(2S,3R)-N-hydroxy-2-[[(2E)-2-hydroxyimino-2-(4-phenylphenyl)ethyl]sulfanylmethyl]-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.1300	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-(sulfanylmethyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.1300	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-benzyl-N’-hydroxy-3-[[(2Z)-2-hydroxyimino-2-phenylethyl]sulfanylmethyl]butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.1300	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-benzyl-N’-hydroxy-3-(thiophen-2-ylsulfanylmethyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.1600	uM
(2R)-N-[(2S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl]-2-(cyclopentylmethyl)-N’-hydroxybutanediamide	44531: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line)	ic50	0.2000	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-benzyl-N’-hydroxy-3-(phenacylsulfanylmethyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.2100	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-[(6-fluoronaphthalen-2-yl)methyl]-N’,3-dihydroxybutanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.2200	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’,3-dihydroxy-2-(naphthalen-2-ylmethyl)butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.2300	uM
(3Z)-3-[(1-methylindol-3-yl)methylidene]-2-oxo-1H-indole-5-sulfonamide	166535: Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT release	ec50	0.3130	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-(1,3-benzothiazol-2-ylmethyl)-N’,3-dihydroxybutanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.3200	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-[[2-oxo-2-(4-phenylphenyl)ethyl]sulfanylmethyl]butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	0.3800	uM
(2S,3R)-N,2-dihydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(naphthalen-2-ylmethyl)butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.4000	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-N’,3-dihydroxy-2-(naphthalen-2-ylmethyl)butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.6000	uM
(2R,3S)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-N’,3-dihydroxy-2-[(7-hydroxynaphthalen-2-yl)methyl]butanediamide	91698: Inhibitory activity against IgE receptor	ic50	0.7600	uM
(2R)-N’-hydroxy-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)butanediamide	44536: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 1000-4000	ic50	1.0000	uM
(2R)-N-[(2S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-2-(naphthalen-2-ylmethyl)butanediamide	91698: Inhibitory activity against IgE receptor	ic50	1.0000	uM
(2R,3S)-N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-N’,3-dihydroxy-2-(quinolin-6-ylmethyl)butanediamide	91698: Inhibitory activity against IgE receptor	ic50	1.0000	uM
S-[(2S,3R)-3-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]carbamoyl]-2-(hydroxycarbamoyl)-5-methylhexyl] ethanethioate	44535: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 1000-3000	ic50	1.0000	uM
(3Z)-3-[(5-methoxy-1-methylindol-3-yl)methylidene]-2-oxo-1H-indole-5-sulfonamide	166535: Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT release	ec50	1.4000	uM
(2S)-N-[(2S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-2-phenylbutanediamide	44531: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line)	ic50	1.6000	uM
(2R)-N-[(2S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-2-(2-methylpropyl)butanediamide	44531: Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line)	ic50	1.9000	uM
2-[[(3Z)-3-[(5-methoxy-1-methylindol-3-yl)methylidene]-2-oxo-1H-indol-5-yl]sulfonylamino]acetic acid	166535: Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT release	ec50	1.9400	uM
(2R)-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-N’-hydroxy-2-(2-methylpropyl)butanediamide	44532: Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells	ic50	3.0000	uM

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases mutagenesis, affects methylation	2
pimagedine	decreases reaction, increases expression	1
perfluorooctanoic acid	increases expression	1
ethinyl estradiol-desogestrel combination	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
Decitabine	affects expression	1
Acetaminophen	decreases expression	1
Arsenic	decreases methylation	1
Cadmium	increases abundance, increases expression	1
Cisplatin	affects expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Lead	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Methylprednisolone	affects binding, decreases reaction, increases reaction, increases expression	1
Nitrites	affects chemical synthesis	1
Tretinoin	increases expression	1
Methacholine Chloride	increases expression	1
Cadmium Chloride	increases expression, increases abundance	1
Particulate Matter	increases expression, increases reaction	1

ChEMBL screening assays

14 unique, capped per target: 13 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL651875	Binding	Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 50-150	Selective inhibition of low affinity IgE receptor (CD23) processing. — Bioorg Med Chem Lett
CHEMBL769865	Functional	Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT release	Potent small molecule inhibitors of spleen tyrosine kinase (Syk). — Bioorg Med Chem Lett

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1S1	Abcam HeLa FCER2 KO	Cancer cell line	Female
CVCL_B8FV	Abcam HCT 116 FCER2 KO	Cancer cell line	Male
CVCL_B8VP	Abcam MCF-7 FCER2 KO	Cancer cell line	Female
CVCL_B9I2	Abcam A-549 FCER2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.